{ Banner Image }
搜索此博客

订阅更新

最近的帖子

博客编辑器

博客贡献者

尽管没有受伤,联邦法院仍为PFAS暴露提供医疗监测

本月初,美国俄亥俄州南部地区地方法院驳回了3M公司,杜邦,Chemours和其他化学公司在与PFAS化学品有关的集体诉讼中提出的驳回动议的动议。 Hardwick诉3M公司, Case No. 2:18-cv-1185 (S.D. 俄亥俄). The court held that the named plaintiff had properly alleged an 受伤-in-fact for purposes of Article III standing and 俄亥俄 law by claiming that he was exposed to 财务会计准则 chemicals and that 财务会计准则 have been linked to negative health outcomes, despite arguments by the chemical companies that he had not suffered an actual, compensable 受伤.  

投诉’该指控与来自全国各地与PFAS相关的其他诉讼相似。具名的原告声称他被告暴露’ 财务会计准则 chemicals in firefighting foam, and that he now faces an increased risk of disease as a result of his exposure to these chemicals. He sought injunctive relief for his alleged 受伤 in the form of medical monitoring and the appointment of a scientific research panel.

这些化学公司之所以要求驳回诉讼,是因为除其他原因外,指定的原告没有声称他因接触PFAS而遭受任何人身伤害,但法院驳回了这一论点。法院解释说,该名原告已充分指控其受伤,原因是该指控称他由于被告目前体内含有PFAS化学物质’行为以及PFAS化学药品增加了他患病的风险。法院补充说“injury”被原告纠正’s requested relief, 医学监测和研究。

化工公司还争辩说,要求禁制令的救济,特别是任命科学研究小组,超出了联邦法院’拥有平等的宪法权利,但法院在此也不同意。法院认为,法院具有纠正过去错误的广泛平等权力,在驳回动议阶段,法院无需确定如果准予救济将采取的确切形式。因此,法院允许原告’要求前进。